IP Library Granted Patent US 6,846,816
Granted Patent B2
US 6,846,816 · App. 10/347,714 · Granted Jan 25, 2005

Combinations of drugs for the treatment of neoplastic disorders

Assignee: CombinatoRx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,846,816
App. No.
10/347,714
Granted
Jan 25, 2005
Kind
B2
Abstract

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Claims (29)

1. A method for treating a patient having cancer, said method comprising administering to said patient:

a) a first compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of:

R 10 is selected from the group consisting of:

each of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is, independently, H, OH, F, OCF 3 , or OCH 3 ; and W is selected from the group consisting of:

and

b) a second compound having the formula (II):

or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N; each of R 11 and R 12 is, independently, H, Cl, Br, OH, OCH 3 , OCF 3 , NO 2 , and NH 2 ; n is an integer between 2 and 6, inclusive; and each of R 13 and R 14 is, independently, selected from the group consisting of:

wherein said first and second compounds are administered simultaneously or within 14 days of each other in amounts sufficient to treat said patient.

2. The method of claim 1 , wherein said first and second compounds are administered within ten days of each other.

3. The method of claim 2 , wherein said first and second compounds are administered within five days of each other.

4. The method of claim 3 , wherein said first and second compounds are administered within twenty-four hours of each other.

5. The method of claim 1 , said method further comprising administering to said patient one or more a chemotherapeutic agents selected from paclitaxel, docetaxel, tamoxifen, vinorelbine, gemcitabine, cisplatin, etoposide, topotecan, irinotecan, anastrozole, rituximab, trastuzumab, fludarabine, cyclophosphamide, gentuzumab, carboplatin, interferon, 5-FU, doxorubicin, and cytoxan.

6. The method of claim 5 , wherein said first and second compounds are administered within ten days of each other.

7. The method of claim 6 , wherein said first and second compounds are administered within five days of each other.

8. The method of claim 7 , wherein said first and second compounds are administered within twenty-four hours of each other.

9. The method of claim 1 , wherein said cancer is brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, or uterine cancer.

10. The method of claim 9 , wherein said first and second compounds are administered within ten days of each other.

11. The method of claim 10 , wherein said first and second compounds are administered within five days of each other.

12. The method of claim 11 , wherein said first and second compounds are administered within twenty-four hours of each other.

13. A method for treating a patient having brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, or uterine cancer, said method comprising administering to said patient:

a) a first compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of:

R 10 is selected from the group consisting of:

each of R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is, independently, H, OH, F, OCF 3 , or OCH 3 ; and W is selected from the group consisting of:

and

b) a second compound having the formula (II):

or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N; each of R 11 and R 12 is, independently, H, Cl, Br, OH, OCH 3 , OCF 3 , NO 2 , and NH 2 ; n is an integer between 2 and 6, inclusive; and each of R 13 and R 14 is, independently, selected from the group consisting of:

wherein said first and second compounds are administered simultaneously or within 24 hours of each other in amounts sufficient to treat said patient.

Assignments (2)
CHANGE OF NAME Recorded Oct 15, 2010
From: COMBINATORX, INCORPORATED
To: ZALICUS INC.
Reel/Frame 025150/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2004
From: BORISY, ALEXIS; KEITH, CURTIS; FOLEY, MICHAEL A.; STOCKWELL, BRENT R.
To: COMBINATORX, INCORPORATED
Reel/Frame 014326/0370 →
Continuity (2)
Continuation 0970692900 · Nov 6, 2000
Related Publication 20030166642A1 · Sep 4, 2003